
1. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2235-9.

Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

Ludovici DW(1), De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW,
Andries K, de BÃ©thune MP, Azijn H, Pauwels R, Lewi PJ, Heeres J, Koymans LM, de
Jonge MR, Van Aken KJ, Daeyaert FF, Das K, Arnold E, Janssen PA.

Author information: 
(1)Janssen Research Foundation, Welsh and McKean Roads, Spring House, PA 19477,
USA.

The synthesis and anti-HIV-1 activity of a series of diarylpyrimidines (DAPYs)
are described. Several members of this novel class of non-nucleoside reverse
transcriptase inhibitors (NNRTIs) are extremely potent against both wild-type and
a panel of clinically significant single- and double-mutant strains of HIV-1.

DOI: 10.1016/s0960-894x(01)00412-7 
PMID: 11527705  [Indexed for MEDLINE]

